Skip to main content
. 2010 Dec 7;25(2):341–347. doi: 10.1038/leu.2010.226

Figure 2.

Figure 2

(a) Dose-dependent inhibition of mantle cell proliferation (Jeko) and diffuse large B-cell lymphoma cell proliferation (DHL6) with the mTOR inhibitor everolimus. (b) Treatment of three MCL cell lines with everolimus has little effect on cell survival.